Interferon alfa-2a

Br J Hosp Med. 1997 May;57(9):436-9.

Abstract

Interferon alfa-2a shows both antiviral and antitumoral activity, but its role in the treatment of many conditions remains controversial. It is, however, the treatment of choice for chronic, active hepatitis B, chronic hepatitis C and AIDS-related Kaposi's sarcoma, and is also effective in metastatic renal carcinoma and chronic myelogenous leukaemia. Optimal dose regimens are unclear, and further randomized trials are needed.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Hepatitis B / therapy
  • Hepatitis C / therapy
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Kidney Neoplasms / therapy
  • Leukemia, Hairy Cell / therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Lymphoma, Non-Hodgkin / therapy
  • Multiple Myeloma / therapy
  • Recombinant Proteins
  • Sarcoma, Kaposi / therapy

Substances

  • Antineoplastic Agents
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins